All In Biotech

NDA 020873 · Sandoz

Angiomax

Bivalirudin · Intravenous · Anti-coagulant; Direct Thrombin Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Jul 2, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Dec 15, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

74

21 Phase 3, 6 recruiting

FAERS reports

992

906 serious, 155 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 10, 2025.

Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).( 1 )

Mechanism: Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework, which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release. The...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ANGIOMAX · BIVALIRUDIN 250MG/VIAL · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bivalirudin" as an intervention, any sponsor and status, largest first.

All 74 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective200
  • off label use114
  • haemorrhage91
  • heparin-induced thrombocytopenia76
  • gastrointestinal haemorrhage45
  • thrombosis44
  • vascular stent thrombosis40
  • acute myocardial infarction36
  • hypotension33
  • thrombosis in device33
  • product use issue29
  • cardiac arrest25

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200421
200517
200617
20077
200813
200923
201024
201122
201229
201331
201446
201527
201632
201726
201829
201947
202065
202184
202293
202393
2024100
202591
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Angiomax* (Bivalirudin*) · HCPCS J0583

2024 spending

$781

Beneficiaries

15

16 claims

Per beneficiary

$52

2024 ASP limit $0.21 per unit

View as table
YearSpending
2020$17,430
2021$14,094
2022$10,757
2023$3,810
2024$781

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 412 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.